Graftskin (Apligraf®) is a tissue-engineered skin product that has been shown in randomized clinical trials to significantly accelerate healing in the treatment of venous ulcers, especially those greater than one year in duration, as well as diabetic foot ulcers. We hypothesize that it may also be effective in the treatment of other types of wounds, such as pressure ulcers and acute wounds. Furthermore, we hypothesize that Graftskin might be maximally effective when used in conjunction with other types of therapy. In this paper, we report on our results from the treatment with Graftskin of pressure ulcers and acute wounds. We show that stage II and III pressure ulcers rapidly heal after Graftskin application on an average of 29 days. Graftskin is also effective in the treatment of acute and chronic wounds. Graftskin is now part of the surgical armamentarium and should be used in conjunction with other standards of care, such as pressure relief, elimination of drainage, and the treatment of local infection.
|Original language||English (US)|
|Issue number||5 SUPPL. A|
|State||Published - Dec 1 2000|
ASJC Scopus subject areas